ACHV

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002, for Sonus Pharmaceuticals, Inc. (Note: The input metadata listed "ACHIEVE LIFE SCIENCES, INC.", but the filing text explicitly identifies the registrant as Sonus Pharmaceuticals, Inc.). Sonus is a clinical-stage biopharmaceutical company focused on its TOCOSOL drug delivery technology. The company's lead product candidate, TOCOSOL Paclitaxel, is currently in Phase 2 clinical trials for various cancers.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: The company reported no revenue in Q3 2002, a significant decrease from $7.6 million in Q3 2001. The prior year revenue was driven by a $6.5 million payment from Nycomed Amersham plc for intellectual property assignment and a $1.0 million license fee from Chugai Pharmaceutical Co. Ltd.
• Expense Increase: Total operating expenses rose to $3.4 million in Q3 2002 from $2.5 million in Q3 2001. This increase was primarily due to higher Research and Development (R&D) costs ($2.6 million vs. $1.3 million) associated with advancing TOCOSOL Paclitaxel into Phase 2 trials.
• Profitability Shift: The company swung from a net income of $5.2 million in Q3 2001 to a net loss of $3.3 million in Q3 2002. For the nine-month period, the net loss was $9.2 million compared to net income of $2.7 million in the prior year.
• Liquidity Position: Cash, cash equivalents, and marketable securities increased to $19.2 million at September 30, 2002, from $15.1 million at December 31, 2001. This increase was largely due to $12.5 million in net proceeds from a private placement of common stock in January 2002.

Guidance, Outlook, and Risks

• Capital Requirements: Management estimates that existing cash resources will be sufficient to meet requirements through 2003. However, substantial additional capital will be needed to complete late-stage clinical trials and regulatory approval. The company anticipates a net cash burn of approximately $13.0 to $14.0 million for the full year 2002.
• Development Progress: TOCOSOL Paclitaxel is in Phase 2 trials for non-small cell lung, ovarian, bladder, and colorectal cancers. Preliminary data from dose escalation stages showed disease control rates ranging from 37% to 89% across indications. A second product candidate, TOCOSOL Camptothecin, is in late-stage preclinical studies with an anticipated IND filing by the end of 2002.
• Risks: Key risks include the uncertainty of clinical trial results, the lengthy and expensive regulatory approval process, dependence on third-party manufacturers (Gensia Sicor) and suppliers, and the need for future equity or debt financing which may result in dilution or restrictive covenants.
• Market Risk: The company holds a portfolio of marketable securities. Management states that a hypothetical 100 basis point increase in interest rates would not materially affect the fair value of the portfolio.

Investor Verification Checklist

• Verify the status and enrollment numbers of the four ongoing Phase 2 clinical trials for TOCOSOL Paclitaxel.
• Confirm the timeline and funding requirements for the anticipated IND filing for TOCOSOL Camptothecin.
• Assess the sufficiency of the $19.2 million cash balance against the projected $13-14 million annual burn rate and future capital needs beyond 2003.
• Review the terms of the manufacturing and supply agreement with Gensia Sicor Pharmaceuticals, Inc.
• Monitor the company's ability to maintain Nasdaq National Market listing requirements, specifically stockholders' equity and bid price.